Disease · MONDO_0005520
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 25 Hydroxy-Vitamin D3 or [25 (OH) D3] vs Placebo: deaths from any cause | 0 of 219 | 0 of 111 | 330 | NCT02802449 | Trial comparisons |
| 25 Hydroxy-Vitamin D3 or [25 (OH) D3] vs Placebo: serious adverse events | 0 of 219 | 1 of 111 | 330 | NCT02802449 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Sepsis | 2 of 134 | 3 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: In-hospital Mortality | 11 of 134 | 13 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Deep Vein Thrombosis | 8 of 134 | 3 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Study Drug Related Adverse Events | 0 of 134 | 0 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Pneumonia | 16 of 134 | 14 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Urinary Tract Infection | 9 of 134 | 6 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: deaths from any cause | 11 of 134 | 13 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D3 vs Placebo: serious adverse events | 0 of 134 | 0 of 133 | 267 | NCT02881957 | Trial comparisons |
| Vitamin D vs Placebo: deaths from any cause | 0 of 65 | 0 of 65 | 130 | NCT00948298 | Trial comparisons |
| Vitamin D vs Placebo: serious adverse events | 4 of 65 | 4 of 65 | 130 | NCT00948298 | Trial comparisons |
| Cholecalciferol vs Placebo: serious adverse events | 0 of 20 | 0 of 18 | 38 | NCT01974245 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005520/comparisons